Taylor Wessing has advised long standing client, Creo Medical Group plc, on its £1.4 million pre-IPO fundraising and subsequent £20 million primary fundraising by means of an IPO on the AIM Market of the London Stock Exchange. The market capitalisation of Creo Medical on admission will be approximately £61.3 million.

Creo Medical is focused on the development and commercialisation of minimally invasive surgical devices, initially in the area of gastrointestinal (GI) surgery and lung cancer. It has over 76 patents granted and 184 pending.

The corporate team was led by client relationship partner Robert Fenner, with support from James Homan and Helen Pantelides, Ann Casey (Tax & Incentives) and Tim Worden (Patents).

Taylor Wessing has advised Creo Medical since its inception in 2003, from “cradle to liquidity” through numerous angel fundraisings and institutional venture capital rounds.

Robert Fenner, London partner commented on the deal: “Creo Medical is right in Taylor Wessing’s sweet spot – an IP growth business in a dynamic industry. The IPO is a great achievement and a testament to management and Creo’s patented medical device technology, all the more so given the recent uncertainties in the macroeconomic environment.”

Cenkos Securities plc acted as broker and nominated adviser.